Oncology Data Advisor - Data Hub: Gastrointestinal Cancers

Appendix Cancer Awareness Month With Thomas Abrams, MD

In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.

Appendix Cancer Awareness Month With Thomas Abrams, MD

Partnering With Patients Through Advocacy With Allison Rosen, MS

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor, patient advocate, and Director of Project ECHO for the American Cancer Society. Ms. Rosen shares...

Rare Disease Day With Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; and Ulka Vaishampayan, MD

In honor of Rare Disease Day on February 28, the Oncology Data Advisor Editorial Board held a live panel discussion that featured updates on rare gastrointestinal cancers from Dr. Thomas Abrams, Assistant Professor of Medicine at Harvard Medical Scho...

Appendix Cancer Awareness Month With Thomas Abrams, MD

Oncology Data Advisor® · Appendix Cancer Awareness Month With Thomas Abrams, MD In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Har...

Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma with Kohei Shitara, MD

Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Me...

Partnering With Patients Through Advocacy With Allison Rosen, MS

Oncology Data Advisor® · Partnering With Patients Through Advocacy With Allison Rosen At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor,...

Tucatinib Plus Trastuzumab Approved for Colorectal Cancer

The FDA has granted accelerated approval to tucatinib (Tukysa®, Seagen, Inc.) with trastuzumab for rat sarcoma (RAS) wild-type human epidermal growth factor receptor 2 (HER2)–positive unresectable or metastatic colorectal cancer (CRC) that has progre...

Tremelimumab Plus Durvalumab Approved For Unresectable Hepatocellular Carcinoma

The FDA has granted approval to tremelimumab (Imjudo®, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). "Patients with unresectable liver cancer are in need of well-tole...

Futibatinib Receives Accelerated Approval for Cholangiocarcinoma

The FDA has granted accelerated approval to futibatinib (Lytgobi®, Taiho Oncology, Inc.) for treatment of previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma (iCCA) with fibroblast growth factor receptor ...